Alnylam (ALNY) Form 144: 3,022 Shares Worth $1.36M Planned Sale

Alnylam Pharmaceuticals (ALNY) filed a Form 144 notifying of a proposed sale of 3,022 common shares with an aggregate market value of $1,362,922.00.

Rhea-AI Filing Summary

Alnylam Pharmaceuticals (ALNY) filed a Form 144 notifying of a proposed sale of 3,022 common shares with an aggregate market value of $1,362,922.00. The shares are to be sold through UBS Financial Services, Inc. on or about 10/03/2025. The filer states these shares were acquired as PSUs from the issuer on 10/01/2025. The notice also discloses a prior sale by Pushkal Garg of 1,455 shares on 08/19/2025 for gross proceeds of $666,989.17. The filer attests there is no undisclosed material adverse information.

Positive

• 3,022 shares identified with an aggregate market value of $1,362,922.00
• Securities to be sold through a registered broker: UBS Financial Services, Inc.
• Acquisition disclosed as PSUs with acquisition date 10/01/2025, showing origin of shares

Negative

• None.

Insights

Equity Compliance Specialist

Form 144 notes an insider sale of 3,022 shares (~$1.36M) via UBS on 10/03/2025.

The filing shows the securities were acquired as PSUs on 10/01/2025, indicating a recent issuance to the insider rather than a long-held position.

The filer also reported a prior sale of 1,455 shares on 08/19/2025 for $666,989.17, which is a factual disclosure of recent trading activity and complies with Rule 144 notice requirements.

Corporate Transactions Analyst

This notice documents a planned brokered sale through UBS and quantifies recent insider transactions.

The sale uses a registered broker (UBS Financial Services, Inc.) and specifies the exchange (NASDAQ), providing clear execution details required by market rules.

All material items in the filing are explicit: number of shares, aggregate value, acquisition type, acquisition date, and prior sale amounts.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ALNY's Form 144 disclose about the proposed sale?

The Form 144 discloses a proposed sale of 3,022 common shares with an aggregate market value of $1,362,922.00, to be executed via UBS on or about 10/03/2025.

How were the shares being sold acquired according to the filing?

The filing states the 3,022 shares were acquired as PSUs from the issuer on 10/01/2025.

Did the filing report any recent sales by insiders?

Yes. The filing shows Pushkal Garg sold 1,455 shares on 08/19/2025 for gross proceeds of $666,989.17.

Which broker and exchange are specified for the sale?

The broker is UBS Financial Services, Inc. and the sale is to occur on NASDAQ.

Does the filer assert any undisclosed material information?

Yes. By signing, the filer represents they do not know any material adverse information about the issuer that is not publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001829252
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ALNYLAM PHARMACEUTICALS, INC.
SEC File Number	001-36407
Address of Issuer	675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MASSACHUSETTS 02142
Phone	(617) 551-8200
Name of Person for Whose Account the Securities are To Be Sold	Garg Pushkal
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010	3022	1362922.00	131079015	10/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	PSU	Issuer			3022	10/01/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Pushkal Garg 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142	Common	08/19/2025	1455	666989.17

144: Remarks and Signature

Remarks
Date of Notice	10/03/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/11/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Pushkal Garg
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)